logo-loader
viewJohnson & Johnson

Johnson & Johnson starts new UK COVID-19 vaccine trial with 6,000 participants

The pharma giant is looking to see whether two doses can protect patients for longer

Johnson & Johnson - Johnson & Johnson starts new UK COVID-19 vaccine trial with 6,000 participants

Johnson & Johnson (NYSE:JNJ) has started a new late-stage study of its COVID-19 vaccine candidate which will enrol 6,000 people in the UK.

In addition to the ongoing single-dose study, the company’s Belgian arm Janssen is embarking in a trial to assess the efficacy of two doses, with the two assessments running in parallel.

READ: Which Covid vaccine candidates are competing against Pfizer?

The studies follow positive interim results from an ongoing phase 1/2a clinical trials, which showed that the jab induced an immune response and was generally well-tolerated when injected once.

The pharma giant is looking to see whether two doses can protect patients for longer.

It will involve up to 30,000 participants worldwide in Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain, the US, as well as the UK.

Quick facts: Johnson & Johnson

Price: 144 USD

NYSE:JNJ
Market: NYSE
Market Cap: $379.09 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

IXICO signs contract to provide neuroimaging services for clinical trial for...

IXICO PlC (AIM: IXI) Chief Commercial Officer, Lammert Albers joined Steve Darling from Proactive with news the company is to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease. Albers telling Proactive "these services will enable clients to...

15 hours, 21 minutes ago

2 min read